PET/CT Imaging of GRPR Expression in Various Tumors
ConditionMalignancies Multiple
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJewish General Hospital
About this trial
This open-label imaging study will evaluate \[⁶⁸Ga\]-LY4257529 PET/CT, a gastrin-releasing peptide receptor (GRPR)-targeted radiopharmaceutical, in patients with cancers known or suspected to express GRPR. Up to 60 participants will be enrolled in two cohorts: 30 patients with breast cancer and 30 patients with other selected malignancies, including prostate, ovarian, pancreatic, small-cell lung, head and neck squamous cell carcinoma, and other tumors with documented GRPR expression.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
GRPR PET/CT
Diagnostic test\[⁶⁸Ga\]-LY4257529 is an investigational gastrin-releasing peptide receptor (GRPR)-targeted PET radiopharmaceutical. Participants will receive approximately 170 MBq ±20% (4.6 mCi ±20%) intravenously. PET/CT imaging will begin approximately 50-70 minutes after administration to evaluate GRPR-targeted tumor uptake and distribution.
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: [⁶⁸Ga]-GRPR PET/CTExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Per-Patient GRPR PET/CT Detection Rate
Proportion of participants with at least one GRPR-positive lesion on \[⁶⁸Ga\]-LY4257529 PET/CT. Detection rate will be calculated as the number of participants with at least one GRPR-positive lesion divided by the total number of participants in the relevant cancer cohort.
Time frame
After the PET/CT imaging is completedLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Jewish General Hospital
Lead sponsor
Eli Lilly and Company
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: